Cholinergic basal forebrain degeneration due to sleep-disordered breathing exacerbates pathology in a mouse model of Alzheimer’s disease

Received: 17 February 2020
Accepted: 26 September 2022
Published online: 02 November 2022

Lei Qian, Oliver Rawashdeh, Leda Kasas, Michael R. Milne, Nicholas Garner, Kornraviya Sankorrakul, Nicola Marks, Matthew W. Dean, Pu Reum Kim, Aanchal Sharma, Mark C. Bellingham & Elizabeth J. Coulson

Although epidemiological studies indicate that sleep-disordered breathing (SDB) such as obstructive sleep apnea is a strong risk factor for the development of Alzheimer’s disease (AD), the mechanisms of the risk remain unclear. Here we developed a method of modeling SDB in mice that replicates key features of the human condition: altered breathing during sleep, sleep disruption, moderate hypoxemia, and cognitive impairment. When we induced SDB in a familial AD model, the mice displayed exacerbation of cognitive impairment and the pathological features of AD, including increased levels of amyloid-beta and inflammatory markers, as well as selective degeneration of cholinergic basal forebrain neurons. These pathological features were not induced by chronic hypoxia or sleep disruption alone. Our results also revealed that the cholinergic neurodegeneration was mediated by the accumulation of nuclear hypoxia inducible factor 1 alpha. Furthermore, restoring blood oxygen levels during sleep to prevent hypoxia prevented the pathological changes induced by the SDB. These findings suggest a signaling mechanism whereby SDB induces cholinergic basal forebrain degeneration.
more rapid cognitive decline and an increased Aβ burden. However, SDB is not widely recognized as one of the factors that increases the risk of developing AD.

Although the reasons for the epidemiological association between SDB and AD are unclear, there are a number of non-mutually exclusive possibilities. For example, longitudinal studies suggest that the hypoxia which results from SDB causes neurodegeneration, thereby leading to cognitive decline. Similarly, exposure of mice to intermittent hypoxia can exacerbate the accumulation of Aβ and cause neurodegeneration. However, a more recent hypothesis is that disrupted sleep slows the clearance of Aβ from the brain interstitial space through the glymphatic system. Sleep is also considered fundamental for learning and memory consolidation, and poor sleep quality leads to failed memory consolidation. Therefore, SDB-induced sleep disruption could contribute to cognitive impairment and eventually dementia.

The reasons for the increased risk that SDB creates are difficult to determine in humans, even in longitudinal studies, due to the high comorbidity rates of other risk factors such as diabetes and cardiovascular disease in people suffering from the condition. Current animal models of SDB are also limited to a single feature such as chronic hypoxia, intermittent hypoxia induced artificially by rapid cycling of air in a small chamber with varying oxygen concentrations, or sleep disruption. In order to understand the mechanisms linking AD with OSA, we developed a method to model SDB in mice in which breathing and sleep were disrupted coincidently but in the absence of comorbidities. We then used this model to investigate mechanisms by which SDB affects the etiology of key hallmarks of AD.

Results

Urotensin 2-saporin toxin specifically lesions cholinergic mesopontine neurons

Mesopontine tegmentum (MPT) neurons innervate brain regions that are important in REM sleep, such as thalamocortical and the basal forebrain, and are strongly implicated in initiating and maintaining REM sleep. Cholinergic MPT (cMPT) neurons also project to the hypoglossal motor nucleus, which controls the tongue muscles, as well as to other brainstem areas. Respiratory activity in upper airway muscle motor neurons is driven by the brainstem respiratory central pattern generator, and the tongue muscles are important upper airway dilator muscles during inspiration. We, therefore, reasoned that cMPT lesioning would result in upper airway collapse, particularly during REM sleep when acetylcholine activity is highest, providing a mouse model of SDB/OSA.

cMPT neurons selectively express the urotensin 2 receptor, and respond to its ligand, urotensin-2 peptide. To selectively ablate cMPT neurons we used a ribosomal inactivating saporin-conjugated urotensin-2 peptide (UII-SAP) and targeted the lateral dorsal tegmentum (LDT) region rather than the pedunculopontine nucleus (PPN) of the MPT, which is known to mediate locomotion or reward. Direct injection of the UII-SAP toxin into the brainstem induced a unilateral specific loss of cholinergic neurons within the MPT after 2 weeks. In male mice with unilateral loss of cholinergic neurons in the LDT was significantly reduced in the UII-SAP-injected mice (Fig. 1A, B), with a smaller but significant loss of ChAT-positive neurons also being detected in the PPN. A similar loss of cLDT neurons was observed when UII-SAP was injected via the intracerebral ventricle (Fig. 1C), indicating that the reduced number of ChAT-positive neurons was not due to damage at the injection site. However, there was no loss of calbindin-positive GABAergic neurons in the LDT (Fig. 1D) or of cholinergic hypoglossal motor neurons (Fig. 1E). cMPT-lesioned mice displayed no significant change in body weight (see Source Data), distance traveled (Fig. 1F) or anxiety/exploration (Supplementary Fig. 1B) in an open field test, or rotarod performance (Fig. 1G), relative to control-lesioned mice.

cMPT lesions result in sleep-disrupted breathing

Next, we used unrestrained whole-body plethysmography during the lights on period to determine the effect of cMPT lesion on the breathing pattern of lesioned and non-lesioned mice of each sex during their sleep and wake periods as measured by electroencephalography (EEG). We hypothesized that if there was reduced airflow due to resistance of the upper airways of lesioned mice during sleep, peak inspiration volume (PIF) would be reduced and time for inspiration (EIP) increased, and that the time between breaths would be increased, as occurs in humans with OSA. Due to the possible influences of sex, sleep-wake, and lesion, and the number of plethysmography variables measured that make up a breathing cycle, we have summarized the combined data (Fig. 2A–D) in which the average measures for male (Fig. 2E) and female (Sup Fig. 2B) mice were used to draw the stylized breaches. Importantly, during wakefulness, we found no significant differences in the average value of any of the breathing parameters between control and cMPT-lesioned mice of either sex (Fig. 2A, C, E and Source Data). In contrast, a significant effect of the lesion was found on the above breathing measures during sleep (p < 0.001, sleep-wake-paired, two-way ANOVA).

As expected, the average frequency of breaths (f) decreased during sleep compared to wake periods in control animals (Fig. 2C–E). However, breath frequency was also significantly different between males and females (p = 0.0109, sleep-wake paired, two way ANOVA). Surprisingly, the breath frequency during sleep of lesioned mice was on average lower than that of controls and not significantly different from the breath frequency during wakefulness (Fig. 2A–E). However, in lesioned mice of both sexes, the time between breaths during sleep, irrespective of mean frequency, was significantly more variable than that of sleeping control mice (p < 0.0001; Levene test of variance; Fig. 2C). In humans, an apnea is the cessation of airflow for 10 s, which is the time in which a person would typically take three breaths (with a frequency of 12–20 breaths/min while asleep). During sleep, control mice average 5 breaths every 2 s (a rate of 150 breaths/min). However, cMPT-lesioned mice were significantly more likely to have adjoining epochs of reduced breath frequency (<100 breaths/min; p = 0.020, one-tailed unpaired t-test with Welch correction), with 54 and 17% of low frequency breathing epochs lasting longer than 4 s in cMPT-lesioned and control mice, respectively. Interestingly, there was a trend for the long low-frequency breathing periods to be followed by an awake epoch in the lesioned mice, whereas there was no obvious association between low frequency breathing epochs and sleep/wake transitions in the control mice.

In both control and cMPT-lesioned mice, the average PIF was reduced during sleep (Fig. 2D). However, in the lesioned mice the average EIP during sleep was shorter than that of controls, being equivalent to their average EIP during the wake phase. Nonetheless, during sleep, PIF and EIP were more highly variable in the cMPT-lesioned mice than control mice. This indicates that, while on average inspiration flow was slower and took longer, there were both very large and very small peak flow measures and inspiration times in cMPT-lesioned mice during sleep.

As for control mice during sleep, PEF was reduced in lesioned mice of both sexes during sleep—indicative of a slower exhalation period. However, the breathing patterns during exhalation of male (Fig. 2E) and female (Supplementary Fig. 2) mice differed independently of sleep, particularly in average measures of total time to exhale (EEP; p = 0.0212 sleep-wake-paired, two way ANOVA) and for the point in expiration where the peak flow occurs as a fraction of total time to expire (Rpef, p = 0.051); the control male mice had significantly larger
averages of these measures during sleep than females, and as the values for males but not females were significantly reduced in the lesioned groups, a significant interaction with sex and sleep state in EEP was observed ($p = 0.0157$, sleep-wake-paired, two way ANOVA). Nonetheless, the average EEP for sleeping lesioned mice was significantly less than sleeping control mice ($p < 0.0491$, paired two-way ANOVA), and was equivalent to that of awake mice ($p > 0.999$). However, in the male lesioned mice, EEP during sleep was significantly more variable than that of control sleeping animals ($p < 0.0001$; Levene test of variance; Fig. 2C). Despite this, the time for 65% of exhalation to be reached was less variable in both male and female lesioned mice during sleep than for the control mice during sleep ($p < 0.0001$; Levene test of variance; Fig. 2C). As the EEP includes any pause between breaths, these results account for the lesioned mice taking more frequent breaths on average, and also indicates that the lesioned mice, particularly males, exhibit a highly variable length of time between the point of 65% exhalation and the start of the next inhalation.

We also noted that the breathing measures during sleep for individual mice within the lesion group were significantly different for
Fig. 2 | Urotensin II-saporin treatment affects the breathing pattern and induces hypoxemia during sleep. Stylized breathing traces based on the average measures of the polysomnography features recorded by whole body plethysmography and coincident EEG recordings in mice injected with control Blank-SAP (A, C) or UII-SAP (B, D) during wake (A, B) or sleep (C, D). Statistics refer to sleep-wake paired two-way ANOVA and Levene tests of variance of both male and female mice. E Average polysomnography measures for individual male mice in UII-SAP or control Blank-SAP groups (sleep-wake paired two-way ANOVA; mean ± s.d) f frequency, PIF peak inspiration flow, PEF the peak exhalation flow, EIP time for inspiration, EEP time for exhalation, RT: F Average blood oxygen saturation level of unrestrained UII-SAP- and Blank-SAP-injected male mice measured during their sleep period (P < 0.0001, Student’s unpaired two-tailed t-test; mean ± s.e.m). G Representative traces of blood oxygen saturation levels of male mice injected with either UII-SAP or control Blank-SAP. *P < 0.05, **P < 0.01, ***P < 0.001 ****P < 0.0001 n.s: non-significant. Each data point represents an individual animal.
In summary, these data demonstrate that cMPT-lesioned mice have highly variable breathing patterns during sleep that, on average, are consistent with predicted alterations in inhalation and exhalation measures that occur due to upper airway resistance, with breath to breath variability indicative of a recovery response triggered by hypoxia. Most lesioned mice also displayed multi-second periods of reduced breath frequency during sleep, followed by arousal, that could be interpreted as apneic event(s). Furthermore, consistent with the most common forms of SDB, when the blood oxygen saturation of the cMPT-lesioned mice at rest was measured for 30 min during the sleep period, it was found to be between 80% and 90% SpO2, a significant reduction compared with the >95% SpO2 recorded in control mice (Fig. 2F, G). These findings indicate that the cMPT lesion affects breathing pattern, causing mild hypoxia during sleep, which is consistent with an airway obstruction.

cMPT lesion disrupts sleep resulting in a sleep debt

We next analyzed the sleep patterns of the cMPT-lesioned mice to determine if the altered breathing pattern correlated with altered sleep states, as occurs in SDB. Male and female mice were analyzed separately. cMPT lesioning had no effect on total awake time; number of wake bouts or wake bout length during their sleep and active phases (lights on/off; Supplementary Fig. 3A). However, the number of non-REM (NREM) and REM sleep bouts were significantly increased in male mice with cMPT lesions during their sleep phase, with the duration of the NREM bouts being significantly reduced compared to control-lesioned mice (Fig. 3A–C). The number of transitions between REM and NREM sleep and vice versa were also significantly increased (Fig. 3D).

Similar trends to that displayed by the male lesioned mice were observed for female lesioned mice (Supplementary Fig. 3B, C).

We next determined whether the loss of cMPT neurons resulted in a sleep debt. Male mice were individually housed on a 12:12 h light/dark cycle in a PhenoMaster cabinet and their movement was quantified using infrared motion sensors in 10 min blocks. Lesioned mice had an equivalent number of sleep bouts (inactivity-defined sleep) to control mice (Fig. 3E) but of shorter duration (≥10 min long) resulting in significantly less total sleep during the inactive phase (Fig. 3E, F), suggesting that the mice displayed disrupted sleep. To further assess the sleep quality in these mice, a 3 h dim light pulse (30 Lux) was applied during the dark (awake) phase on day 3 of the assessment to induce a

---

**Fig. 3** Urotensin II-saporin treatment affects the sleeping patterns causing sleep deprivation. A Average amount of REM, NREM, and wake sleep during lights on (sleep) and lights off (wake) periods. (P = 0.0264, two-way ANOVA with Tukey’s multiple comparisons test). B Average number of REM, NREM and wake sleep bouts during lights on (sleep) and lights off (wake) periods. (P = 0.0026, two-way ANOVA with Tukey’s multiple comparisons test). C Average length of REM, NREM an wake bouts during lights on (sleep) and lights off (wake) periods. (P = 0.0145, two way ANOVA with Tukey’s multiple comparisons test). D The average number of transitions during the lights on period that lesioned (gray) and UTI-SAP (red) lesioned mice moved between sleep states and sleep and wake (P = 0.010 unpaired two-tailed t-test). E Average number and length of sleep bouts (periods spent inactive lasting at least 10 min. P = 0.5023, P = 0.0475, unpaired two-tailed t-test) and total time spent inactive (P = 0.0475, unpaired two-tailed t-test) during a 12 h light phase for the first 48 h of activity recording. F Total time spent inactive during the 12 h light phase in the first 48 h (P = 0.0014; unpaired two-tailed t-test). G Activity traces of a control and a lesioned mouse over 3 days of in 12:12 h light/dark cycle. On day 3 during the dark phase, mice were exposed to 3 h of 30 Lux dim light. H Time spent active during the 3 h low light period during the 12 h light phase on day 3 of the experiment. (P = 0.04). Mice placed in 40% oxygenated (high O2) for 8 h a day during the sleep period for 2 weeks starting 2 weeks after injection with UII-SAP (purple bar) did not have a sleep debt compared to UTI-SAP-injected mice subjected to normoxia. (P = 0.0286, two-tailed Mann-Whitney test). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 n.s: non-significant. Results are presented as mean ± s.e.m. Each data point represents an individual animal. Source data are provided in the Source Data file.
sleep-conducive environment. The lesioned mice displayed a sleep debt (the human equivalent of daytime sleepiness), showing a greater tendency to sleep during the light pulse (Fig. 3G, H).

To test whether the hypoxia was responsible for the disrupted sleep, we first empirically determined that a high (40%) oxygen environment restored the blood oxygen levels of cMPT-lesioned mice to >95% SpO2. Starting 2 weeks after lesion surgery, male mice were treated daily with high oxygen during their 12h sleep period for 2 weeks while in the PhenoManus cabinet. As expected, high oxygen treatment had no effect on the extent of the cMPT lesion (Supplementary Fig. 3D). Nonetheless, the treatment restored the animals’ sleep patterns, and prevented the development of a sleep debt (Fig. 3H, I), demonstrating that these phenotypes were linked to the induced hypoxia. Taken together, these findings (disrupted breathing during sleep, changed sleep patterns and induction of hypoxia) are consistent with the cMPT lesion inducing a SDB-like phenotype in mice.

cMPT lesion exacerbates the cognitive and pathological features of AD

In order to determine whether the cMPT lesion and associated OSA phenotypes exacerbated the core features of AD (cognitive impairment, amyloid plaques, neuroinflammation, and neurodegeneration), we used the commonly studied APP/PS1 familial AD mouse model. This strain expresses mutant amyloid precursor protein (APPswe) and presenilin 1 (PS1ΔE9), leading to overproduction of Aβ, which aggregates and accumulates into amyloid plaques from around 6 months of age, resulting in cognitive impairment.

We lesioned the cMPT neurons of 8-month-old APP/PS1 mice of both sexes and tested their cognitive function 2 months later. No difference was observed between 10-month-old lesioned and control groups (sham-lesioned APP/PS1 mice) in terms of time spent in the center of an open field (cMPT lesioned = 46.45 ± 3.66 s, sham lesioned = 47.88 ± 4.54 s). However, cMPT-lesioned APP/PS1 mice of both sex displayed severe impairment in hippocampal-dependent learning and memory compared to age-matched unlesioned APP/PS1 mice. In the Y maze, sham-lesioned mice spent significantly more time in the novel arm of the apparatus than in the familiar arm, whereas cMPT-lesioned mice showed no preference (Fig. 4A). In the Morris water maze, APP/PS1 sham-lesioned mice learned the location of the platform during training, whereas the cMPT-lesioned mice did not (day 1 vs day 4: Blank-SAP, P = 0.0039; UII-SAP, P > 0.9999; Fig. 4B). In the probe trial both lesioned and sham-lesioned APP/PS1 mice had similar poor performance (Fig. 4C), likely reflecting memory impairment due to the animals’ age and genotype, irrespective of lesion status. Similarly, in the active place avoidance task, neither lesioned nor control APP/PS1 mice showed significant learning during 4 days of training (Blank-SAP: P = 0.2286; UII-SAP: P = 0.9999; Fig. 4D). However, lesioned APP/PS1 mice exhibited a greater impairment in both the learning (Fig. 4D) and memory (Fig. 4E) components of this task compared to controls. Together these data indicate that cMPT lesion neurons exacerbate cognitive deficits in aged APP/PS1 mice.

To determine whether the cMPT lesions exacerbate the pathological features of AD, we assessed the number of Aβ plaques, as well as the levels of inflammation and neurodegeneration (Fig. 5A). No differences were found between male and female animals, which were analyzed together (Sup Fig. 4). As expected, the APP/PS1 mice injected with UII-SAP at 8 months of age and sacrificed 3 months later displayed significant CLDT neuronal loss (Fig. 5B), equivalent to that of cMPT-lesioned wildtype mice (Fig. 1B). cMPT-lesioned APP/PS1 mice had significantly increased levels of soluble Aβ42 in hippocampal lysates (Fig. 5C), as well as more thioflavin S-positive and 6E10-Aβ plaques in the cortex (Fig. 5A, D, E), compared to sham-lesioned APP/PS1 mice. The levels of microglia (Fig. 5A, F, G) and activated astrocytes (Fig. 5A, H, I) in the cortex of cMPT-lesioned APP/PS1 mice were also significantly higher. We found no evidence of neurodegeneration in the hippocampus or cortex of lesioned APP/PS1 mice by measuring the width of the pyramidal neuron layers (Fig. 5J, K). However, the number of Aβ neurons, a feature of AD that occurs early in the human disease but is not readily observed in the familial mouse models, was significantly reduced in cMPT-lesioned APP/PS1 mice compared to sham-lesioned APP/PS1 mice (Fig. 5L), as was the density of cholinergic axonal innervation to the cortical regions (Supplementary Fig. 5).

Together these results indicate that cMPT lesioning causing SDB, when coupled with a genetic drive to overproduce Aβ, can exacerbate the key pathological and cognitive features of AD in mice.

cBF degeneration is induced by cMPT lesion

Cholinergic basal forebrain (cBF) neurons project to the entire neocortex, regulating cognitive processes including spatial navigation and associative learning. These neurons are among the first to degenerate in AD, with their loss being evident in mild cognitive impairment and idiopathic AD, as well as in individuals who are subsequently diagnosed with cognitive impairment. In humans, Aβ load correlates with basal forebrain atrophy and dysfunction, but it is unclear whether cBF degeneration is a cause and/or effect of Aβ accumulation. In mouse models, oligomeric Aβ can induce cBF degeneration, whereas cBF degeneration can exacerbate Aβ accumulation.

To determine the cause of cBF neuron loss observed in the APP/PS1 mice, we examined the effect of the cMPT lesioning on Aβ survival in male wildtype (C57Bl6) mice over a 7-week period. Significant loss of cLDT neurons was evident by 2 weeks, consistent with the nature of the saporin toxin-induced cell death, with more than 50% of cLDT cells observed at later time points (Fig. 6A). The loss of cBF neurons occurred subsequent to the cMPT lesioning between 2 and 4 weeks after surgery (Fig. 6B), resulting in ~30% loss of cells from the medial septum, as well as the vertical and horizontal diagonal bands of Broca (Supplementary Fig. 6A, B).

Furthermore, the reduction in the number of cBF neurons significantly correlated with the size of the cMPT lesion (r = 0.5746, P = 0.0080, R2 = 0.3302). No change was observed in the number of parvalbumin-positive GABAergic neurons in the basal forebrain (Supplementary Fig. 6C). This cBF degeneration was also sufficient to cause impairment in visuo-spatial memory consolidation. No significant deficits in the Y maze (Supplementary Fig. 6D) or novel object recognition tasks (Supplementary Fig. 6E), were detected by cMPT-lesioned wildtype mice or unlesioned mice. However, in the active place avoidance navigation task many of the cMPT-lesioned mice received more shocks during the training and probe trials than control animals (Fig. 6C). Moreover, in the passive place avoidance task, which requires cBF function, cMPT-lesioned mice displayed a significant memory deficit (Fig. 6D).

Sleep deprivation does not result in cBF neuronal loss or Aβ accumulation

To determine whether the disrupted sleep or hypoxia induced by cMPT lesioning was responsible for causing cBF degeneration and Aβ accumulation, wildtype and aged APP/PS1 mice of both sex were subjected to sleep deprivation using a modified ‘flowerpot’ method (Supplementary Fig. 7A). It is difficult to disrupt NREM sleep, but this method results in a ~30% reduction in NREM sleep (mimicking the
cMPT-lesioned phenotype) as well as almost completely eliminating REM sleep\(^b\). Cohorts of unlesioned mice were placed in sleep-deprivation cages for 20 h a day, returning to their home cage for 4 h a day during their sleep phase. The mice became visually sleepy over the course of the experiment, but maintained their body weight (Supplementary Fig. 7B, C). After 4 weeks of sleep deprivation, APP/PS1 animals displayed deficits in Y maze performance that were not exhibited by age-matched APP/PS1 mice housed in equivalent conditions except that their cages lacked water. However, contrary to expectation, latency to first sleep at the end of the paradigm was driven by age rather than cage type (two-way ANOVA, age: \(P = 0.0113\) cage: \(P = 0.2392\)), with sleep deprivation causing long-lasting effects on the animals’ sleep patterns. Sleep-deprived mice had normal diurnal sleep/wake rhythms (\(P < 0.0001\) rhythmicity, \(P = 0.676\) amplitude, \(P = 0.943\) peak time) but a longer sleep latency and a reduction in total sleep time in the 3 days after the paradigm ended (Supplementary Fig. 7D–F). Nonetheless, the number of cBF neurons in the sleep-deprived mice was not significantly different from that in control mice (Fig. 7B). The levels of soluble and plaque A\(\beta\) (Fig. 7C, D) and degree of inflammation (Supplementary Fig. 7G–J) in the APP/PS1 mice were also unaltered by the sleep deprivation conditions. Taken together, our results indicate that SDB-induced hypoxia rather than sleep deprivation likely causes the cBF degeneration and exacerbates A\(\beta\) accumulation and inflammation. Nonetheless, the reduced inflammation observed in the control mice could be due to their lower level of stress compared to the sleep-deprived cohort, or as a result of their lower A\(\beta\) or acetylcholine levels.

**HIF1\(\alpha\) mediates cBF death following cMPT lesioning**

To test whether the cBF neurons were dying due to exposure to chronic hypoxic conditions, wildtype male mice were exposed to reduced (80%) oxygen conditions for 8 h a day during their sleep period for 4 weeks (Supplementary Fig. 8A). At the end of this period, the number of cBF neurons in mice subjected to daily chronic hypoxia was not significantly different from that of mice housed continuously in normoxia (Fig. 8A), indicating that chronic hypoxia was unable to trigger the same degenerative pathways that were induced by cMPT lesioning. In contrast, chronic intermittent hypoxia (with oxygenation of the air fluctuating from 0 to 100% every 90 s) has been reported to induce cBF neuronal degeneration\(^c\).

To test whether fluctuating hypoxia/normoxia was the trigger for cell death, male cMPT-lesioned mice were treated for 4 weeks with the drug 2-methoxyestradiol (2ME2). This compound binds to and prevents the nuclear translocation of hypoxia-inducible factor 1 alpha (HIF1\(\alpha\)), the expression of which is induced by low oxygen conditions and mediates the transcription of genes such as vascular endothelin growth factor to improve cerebral blood flow and oppose the toxicity of hypoxia. However, prolonged or persistent activation of HIF1\(\alpha\) has also been linked to cell death mediated by pro-apoptotic Bcl-2 family members, e.g., via BNIP3, or increased expression of the reactive oxygen species-generating NOX proteins\(^d\). Two weeks after cMPT lesioning, wildtype mice were injected daily for either 3 (Supplementary Fig. 8B, C) or 4 weeks with 2ME2. As an indication that 2ME2 engaged its target, the percentage of cBF neurons with HIF1\(\alpha\) present in the nucleus (indicative of its activation) in lesioned, untreated animals was significantly higher than that in both treated cMPT-lesioned mice, and sham-lesioned mice (Fig. 8B, C). The extent of cMPT neuron loss was equivalent between 2ME2-treated and untreated lesioned mice, and significantly reduced compared to the cMPT neuron number in sham-lesioned control animals (Fig. 8D; Supplementary Fig. 8B). However, the number of cBF neurons in the 2ME2-treated lesioned animals was significantly increased compared to that in untreated lesioned animals, and similar to that in sham-lesioned mice (Fig. 8E; Supplementary Fig. 8C). The 2ME2-treated
**Fig. 5** cMPT lesion exacerbates major AD hallmarks of lesioned APP/PS1 mice. A Representative photomicrographs of sagittal brain sections of hippocampus and cortex of APP/PS1 mice treated with UII-saporin (6 animals) or control Blank-saporin (6 animals) and stained with thioflavin S (ThS) and 6E10 (both for Aβ plaques), CD68 or GFAP (for microglia and astrocytes). Scale bars = 100 μm. B The average number of ChAT-positive neurons in the LDT of UII-SAP injected APP/PS1 mice was lower than that of APP/PS1 mice injected with Blank-SAP (P = 0.0033). C The amount of soluble Aβ in the hippocampal lysates of APP/PS1 mice treated with UII-SAP as measured by ELISA was higher than that of APP/PS1 mice injected with Blank-SAP (P = 0.0116). The density (D; P = 0.0320) and area (E; P = 0.0432) of thioflavin S-positive Aβ plaque in neocortex of APP/PS1 mice treated with UII-SAP was higher than that of APP/PS1 mice injected with Blank-SAP (P = 0.0033). The thickness of the CA1 pyramidal layer of UII-SAP-injected and Blank-SAP-injected APP/PS1 mice. J The thickness of the somatosensory cortex of UII-SAP-injected and Blank-SAP-injected APP/PS1 mice. L The average number of ChAT-positive basal forebrain (BF) neurons in APP/PS1 mice treated with UII-SAP was lower than that of APP/PS1 mice injected with Blank-SAP (P = 0.0038). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 n.s.: non-significant. Student’s unpaired two-tailed t-test for panels (B–L). Results are presented as mean ± s.e.m. Each data point represents an individual animal. Source data are provided in the Source Data file.
mediated by high endogenous HIF1 that the loss of cholinergic cBF neurons following cMPT lesioning is equivalent to that of sham-lesioned mice (Fig. 8G). These data indicate the extent of cMPT neuron loss was significantly reduced in cMPT-lesioned mice to >95% SpO2 during their sleep phase (Fig. 3H). Starting 2 weeks after lesion surgery, aged APP/PS1 mice of both sexes were treated daily with high oxygen during their 12 h sleep period for 4 weeks. This treatment had no effect on the extent of the cMPT lesion were treated daily with high oxygen during their 12 h sleep period for 4 weeks. This treatment had no effect on the extent of the cMPT lesion and cognitive impairment, two early features of AD, the mechanisms underlying this increase risk are unclear. Preventing hypoxia prevents AD features after cMPT lesion

The standard treatment for OSA in human suffers is the use of continuous positive airway pressure (CPAP) therapy during sleep, which physically maintains airway opening and thus prevents blood oxygen desaturation and arousal from sleep. We therefore asked whether treatment of the SDB mice during their sleep phase with a high-oxygen environment could protect cBF neurons from the cMPT lesion-induced cell death and/or Aβ accumulation. We again used the high (40%) oxygen environment to restore the blood oxygen levels of cMPT-lesioned mice to >95% SpO2 during their sleep phase (Fig. 3H).

Discussion

Despite strong epidemiological links between SDB and the development of AD, the mechanisms underlying this increased risk are unclear. Here we developed a model of SDB in mice that replicates key features of the human condition without comorbid risk factors such as cardiovascular disease and diabetes. Using our model, we demonstrated that cBF neurodegeneration and cognitive impairment, two early features of AD, the mechanisms underlying this increased risk are unclear. Preventing hypoxia prevents AD features after cMPT lesion
The CmPT-lesioned mice had disrupted sleep patterns, with increased
sleep apnea (age: \( P = 0.0330 \), cage: \( P = 0.9852 \), interaction: \( P = 0.6177 \)) and cortex (age: \( P = 0.0128 \), cage: \( P = 0.410 \), interaction \( P = 0.666 \)) of APP/PS1 mice was affected by
age but not by sleep deprivation. \( * P < 0.05 \), \( ** P < 0.01 \), \( *** P < 0.001 \), \( **** P < 0.0001 \),
N.s., non-significant. Two-way ANOVA, Sidak’s multiple comparisons for panels
(A, C, and D). Results are presented as mean of pooled age groups ± s.e.m. Each data
point represents an individual animal. Source data are provided in the Source
Data file.

features of AD, are induced by intermittent hypoxia and that, in a
genetically susceptible (familial) AD mouse, SDB exacerbates addi-
tional pathological features such as plaque load and inflammation. In
contrast, although chronic sleep deprivation (for an equivalent period
of time to that in which mice were subjected to SDB) impaired working
memory of mice, it neither induced cBF neuronal dysfunction nor
exacerbated Aβ accumulation. This suggests that fluctuating hypoxia
is a major mechanism by which SDB, even in the absence of comor-
bidities, could promote AD in humans.

Urotensin 2-saporin toxin lesion of the CmPT replicates key
features of human SDB
Hallmarks of patients with untreated SDB include recurrent nocturnal
arousals from sleep, caused by frequent episodes of pharyngeal
obstruction. These cause hypopneas (≥4% decrease in arterial oxygen
saturation\(^1\)), and hypoxemia (<85% \( S_H_2_0 \) during sleep), resulting in
wakefulness and frequent sleep interruptions. Our model displays
hallmarks of a form of flow-limited SDB. CmPT-lesioned mice exhibited
disrupted and variable breathing characteristics during sleep, specif-
ically in EIP, PIF, EIP, and RT, and highly variable breathing frequency and
tidal volume, which is consistent with upper airway resistance and
subsequent recovery from hypoxia\(^1\). Furthermore, the mice exhib-
ited hypoxemia, another feature of SDB with hypoxia, comparable to
patients with moderate to severe oxygen-desaturation indices. Finally,
the CmPT-lesioned mice had disrupted sleep patterns, with increased
transitions between REM and NREM sleep, reduced NREM sleep, and
shorter sleep bouts that resulted in a sleep debt, the equivalent of
human daytime sleepiness.

Although we cannot rule out the possibility that either the CmPT
lesion or the resultant cBF neuronal degeneration contributed to the
sleep phenotype independently of airway resistance, our data do not
fit simply with such a conclusion. Stimulation (rather than inhibi-
tion) of neurons in the MPT suppresses NREM sleep phenotypes, and
previous studies of lesions of the LDT report a minimal effect on
REM sleep\(^1\). Similarly, inhibition of CmPT neurotransmission would
be predicted to lengthen the time in NREM and shorten REM sleep
bouts, the opposite to what we observed. Furthermore, we have
previously reported that cBF-lesioned mice tend to take longer to
rest during the light cycle, and are more active in the dark/active
cycle\(^1\). In addition, cBF neuron lesions did not impair Y maze
performance\(^1\), whereas mice with the CmPT lesions or who have
undergone sleep disruption have altered responses in this task,
suggesting that mice with (only) cBF lesions are not sleep deprived.
Nonetheless, control of breathing is regulated not only by upper-
airway collapsibility, pharyngeal muscle responsiveness, and arousal
thresholds, but also by ‘loop gain’—the propensity of a system gov-
erned by feedback loops to develop unstable behavior, which is
applicable to both central and obstructive forms of sleep apnea\(^1\). As
both MPT and BF nuclei are heterogeneous, selective cholinergic
lesioning may have disrupted the balance of neurotransmission,
SDB induces pathological hallmarks of AD

Untreated elderly patients with OSA exhibit cognitive decline at twice the rate, and develop AD at an earlier age, than the general population\textsuperscript{5,6}. Similarly, in our study, induced SDB in older APP/PS mice (already predisposed to overproduce Aβ peptides) resulted in more severe cognitive impairment than that observed in their age-matched littermates, and exacerbated many of the pathological features of AD, including induction of cBF degeneration, Aβ accumulation within the cortex and hippocampus, and increased inflammation represented by astro- and gliogenesis. However, even in the absence of a predisposition to AD pathology, SDB sequelae caused cBF degeneration and cognitive decline. cBF degeneration is associated with mild cognitive impairment in both humans\textsuperscript{17} and rodents, particularly impairing higher order cognitive functions, such as allocentric and egocentric navigation, as measured in place avoidance tasks\textsuperscript{34,43,53}. Although the hippocampal-dependent, spatial memory impairment of cMPT-lesioned APP/PS mice occurred concurrent with increased Aβ pathology (in the absence of hippocampal degeneration), the coincident cBF neuronal degeneration likely contributed to the behavioral phenotype\textsuperscript{11}. These results indicate that even in the absence of other comorbidities, SDB can induce or enhance a range of phenotypes associated with AD development. However, as not everyone with SDB develops dementia, it will also be important to understand the characteristics of SDB that increased the development of AD phenotypes.
Intermittent hypoxia underpins the risk of promoting AD features

Sleep deprivation is well known to cause reversible cognitive impairment in humans (e.g., ref. 56), and disruption of glymphatic system function, which can clear Aβ from interstitial fluid and is active during sleep, has been proposed as a mechanism by which poor sleep could increase Aβ deposition or change Y maze performance. However, sleep deprivation alone was not sufficient to increase Aβ deposition or change Y maze performance in young wildtype animals. We cannot rule out a contribution to AD phenotypes, poor glymphatic clearance, or sleep disruption in our SDB model or in patients, particularly if sleep disruption causes persistent changes to sleep levels over a longer period. However, our results suggest that another feature of SDB, intermittent hypoxia, contributes more significantly to the progression of AD pathology than sleep disruption.

We determined that the death of cBF neurons was induced by cMPT lesioning but not by exposure to daily chronic hypoxia. Nonetheless, inhibition of HIF1α activity by 2ME2 or downregulation of HIF1α expression by heterozygous gene deletion in cBF neurons prevented their loss in cMPT-lesioned mice. These results indicate that cBF degeneration induced by SDB is dependent on cell-autonomous hypoxia/HIF1α-regulated pathways. Our conclusion is consistent with other reports in which rats exposed to intermittent hypoxia for 14 days (alternating 90 s epochs of 21 and 10% O2 during sleep) developed deficits in water maze spatial memory performance and reductions in cBF neuron number that mirror the reduction in our SDB model15.

Fig. 9 | High oxygen treatment protects from OSA-exacerbated AD phenotypes. Number of cLDT (A) and cBF (B) neurons in APP/PS1 mice injected with UII-SAP and either the untreated (normoxia, normal oxygen) or treated daily with high oxygen. Number (C; P = 0.0320) and area (D; P = 0.0432) of thioflavin-S-positive Aβ plaques in the neocortex of APP/PS1 mice injected with UII-SAP and treated with normoxia or high oxygen. Density (E; P = 0.0056) and area (F; P = 0.0432) of GFAP-positive microglia in the neocortex of APP/PS1 mice injected with UII-SAP and treated with normoxia or high oxygen. Density (G; P = 0.0098) and area (H; P = 0.0264) of CD86-positive astrocytes in the neocortex of APP/PS1 mice injected with UII-SAP and treated with normoxia or high oxygen. * P < 0.05, ** P < 0.01, n.s., non-significant. Student’s unpaired two-tailed t-test for panels (A–H). Results are presented as mean ± s.e.m. Each data point represents an individual animal. Source data are provided in the Source Data file.
This conclusion is consistent with correlative findings from human populations. The cognitive decline in OSA is linearly correlated with hypoxemia, and a diagnosis of dementia in OSA patients has been associated with the extent of hypoxia rather than sleep disruption. Cognitive impairment is also more common and more severe in OSA patients with hypoxemia.

Additional studies will be required to determine the physiologically relevant tissue-specific levels of hypoxia in our model, and the degree of oxygen volatility required to induce degenerative HIF1α-activated pathways in cBF neurons. Nonetheless, our work highlights fluctuations in hypoxia as the likely major factor in SDB that causes degenerative changes associated with AD.

**cBF degeneration is an early AD feature that can drive other AD features**

Our finding that SDB exacerbates Aβ accumulation in genetically susceptible AD mice is consistent with a previous report that exposure of mice to chronic intermittent hypoxia increases Aβ42 levels in a triple AD model mouse. Similarly, higher brain Aβ, or decreased Aβ and increased phosphorylated tau in the cerebrospinal fluid, has been associated with a higher oxygen desaturation in cognitively impaired OSA subjects. One explanation for these observations could be that hypoxia and HIF1α-mediated transcription can directly up-regulate the expression of β-secretase, while HIF1α can operate as a regulatory subunit of γ-secretase during hypoxia, both of which could increase Aβ production via the amyloidogenic pathway. However, exacerbation of Aβ accumulation in mice that are already overproducing the peptide could also have occurred through an indirect mechanism, specifically cBF degeneration. Although in this study, we did not determine whether cBF degeneration occurred in parallel with, or exacerbated the other AD pathology, previous research strongly implicates the latter.

**cBF neuronal lesioning in a range of mouse AD models exacerbates many features of AD, including promoting cognitive impairment, and increasing Aβ accumulation, plaque load, and inflammation (as observed herein), as well as causing tau hyperphosphorylation, hippocampal degeneration, and reduced neurotrophin expression.** On the other hand, AD model rodents with increased cBF connectivity or those which are treated with muscarinic receptor agonists display cognitive improvements and significantly reduced age-dependent Aβ accumulation and inflammation compared to control rodents. Cholinergic activation of muscarinic receptors also stimulates non-amyloidogenic APP processing, thereby regulating the levels of Aβ in the interstitial fluid. Similarly, in human subjects, reduced basal forebrain volume (as measured by structural MRI, and indicative of cholinergic degeneration) predicts Aβ burden and is evident in mild cognitive impairment and idiopathic AD cohorts, as well as in individuals who are subsequently diagnosed with cognitive impairment. Furthermore, basal forebrain degeneration, together with the accumulation of Aβ, precedes and causes entorhinal cortical degeneration in humans. Therefore, it is probable that the hypoxia-induced death of cBF neurons directly contributed to the other AD phenotypes in our SDB model, and may represent a decisive factor in the etiology of idiopathic AD. Determining the extent of cBF degeneration in people suffering from intermittent hypoxia as a result of SDB would test this interpretation.

Finally, the effect of preventing hypoxemia and sleep disruption in our SDB mice during their daily sleep period, protected against the development of the phenotypes associated with AD. The direct equivalent treatment for humans would be sleeping in a hyperbaric chamber, but high levels of oxygen is not necessarily healthy (e.g. it can result in oxidative stress). However, emerging studies indicate that CPAP treatment of people with OSA to reduce their hypoxia may reduce neurodegeneration and delay the progression of cognitive impairment, particularly that relating to attention and executive function in which cBF neuronal function is strongly involved. The implication of these studies, together with our findings that the prevention of hypoxemia during the sleep period in cMPT-lesioned mice reduced cBF degeneration and Aβ accumulation, is that early diagnosis and treatment of OSA with CPAP may significantly decrease the longitudinal risk of developing irreversible cognitive impairment. Our study therefore provides a rational impetus to longitudinally study CPAP as a prophylactic treatment to reduce the incidence of AD in people with SDB.

In summary, our results suggest that SDB, even in the absence of other comorbidities, is a risk factor for the development of AD. Specifically our work highlights hypoxia as the decisive feature, as it induces cBF neuronal degeneration and cognitive impairment, with a coincident or subsequent increase in the levels of Aβ when linked to a genetic risk for Aβ accumulation (potentially including an ApoE-ε4 genotype). Although treating the hypoxemia in our SDB model or giving CPAP in humans reduces respiratory disturbance during sleep, and improves working memory, some cognitive aspects such as complex attention and executive function remain impaired, daytime sleepiness can continue, and Aβ load can remain unchanged, all of which might reflect irreversible cBF neuronal loss that predates the commencement of CPAP treatment. Therefore, targeting cholinergic function (through cholinesterase inhibition or muscarinic agonists) or specific HIF1α pathways (2ME2 is a current treatment for tumor angiogenesis) represents a candidate strategy for preventing AD in the SDB ‘at risk’ population – those with intermittent hypoxia.

**Methods**

**Animals**

C57BL/6, APP/PS1 (JAX #34832), and ChAT-IRES-cre (JAX #006410) × HiFl1α/fl1α; sourced from the Victor Chang Cardiac Research Institute and outcrossed to C57BL/6 prior to heterozygous breeding for experimental use) mice were maintained on a 12 h light/dark cycle in Optimouse cages with ad libitum access to water and food (Speciality Foods, SF00-100, and SF00-105; the latter for animals aged 1 year and older). Littermates of the same sex were randomly assigned to experimental groups and used at 8–12 weeks or 8 months (for APP/PS1 mice) of age unless stated otherwise; both male and female APP/PS1 mice were used and results were combined as no differences were found between sexes. In other experiments, males and females were analyzed separately unless otherwise stated, or all male cohorts were used due to their more severe SBD phenotype. All procedures were approved by the University of Queensland Animal Ethics Committee (approval numbers 2012/AEOO0407, 2012/AEOO0029, 2015/AEOO00354, 2015/AEOO00084, 2018/AEOO0566, and 2018/AEOO0135) and conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.

**Surgery**

Standard surgical procedures were followed for stereotaxic injection. Animals were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and the muscle relaxant xylazine (10 mg/kg; lesion surgery) or 2–3% isoflurane in 100% oxygen (radiotelemetry implants). Mice received post-operative 0.1 mg/ml Meloxicam (Troy Laboratories) subcutaneously for three days. To induce cholinergic mesopontine tegmentum (cMPT) lesions, bilateral injections of utoxinsin II-saporin (UII- SAP; 0.07 μg/μl per site—unless stated otherwise; generous gift from Advanced Targeting Systems) in the laterodorsal tegmental nucleus (LDT; AP, –3.0 mm; ML, ±0.5 mm; DV, –4.0 mm from Bregma, with the angle 34° backward) were made using a calibrated glass micropipette through a Picopress® II (Parker Hannifin), with the same molar mass of blank-saporin (Blank-SAP) or IgG-saporin (IgG-SAP) as control.
To measure sleep states, we used HD-X02 radiotelemetry implants from Data Science International to measure electroencephalography (EEG), electromyography (EMG), and activity rhythms (for details see refs. 84, 85). The EEG electrodes were placed epidurally above the motor cortex (AP+1, ML+1 mm left from bregma) and the visual cortex (AP−3, ML+3 mm right from bregma). EEG electrodes were fixed with glass ionomer cement (Kent Dental). EMG electrodes were anchored in the trapezius muscle. The scalp was closed using nonabsorbable 6-0 suture material (Ethicon, USA). Approximately 7% of Blank Sap-treated mice and 12% of UII-SAP-treated mice were excluded due to health reasons related to the surgical procedure. Where UII-SAP-treated mice did not show >10% cell loss form he mean of the control cMPT cell number they were excluded from other lesion group analyses.

**Phenotypic analysis**

Behavioral experiments were always performed in the light cycle. Although this was during the animals’ sleep cycle, we reasoned, that this timing permitted sleep-deprived animals to have a chance to sleep prior to the testing. Some cohorts of mice were subject to multiple behavioral tests.

**Sleep assessments.** Two weeks after electrode placement surgery, EEG and EMG were recorded for up to 48 h at a sampling frequency of 500 Hz and captured by the Ponemah 6.4 software (DSI, USA). EEG and EMG recordings were scored in 4 s epochs by the automated rodent sleep-scoring software, NeuroScore 3.0 as wake, REM or non REM (NREM) sleep. Sleep scoring was also supported through video surveillance and an expert assessor. REM sleep bouts were only considered if they were ≥ 1 s long. Two control mice in which overt brain damage was observed due to electrode placement were excluded from the analysis.

A separate cohort of mice was assessed over 72 h for sleep/wake parameters using a metabolic phenocage system (Phenomaster; TSE Systems) with ActiMot light sensors of movement and pre-programmed control of light cycles and light brightness. Mice were considered to be asleep if they had ≥10 min of no movement.

**Whole-body plethysmography.** Following EEG, mice were assessed using whole body plethysmography60 for up to 4 h to record respiration while simultaneously recording EEG in otherwise unrestrained, freely moving mice. The mice were placed in a plethysmograph chamber (Buxco FinePointe Series WBP, DSI) continuously filled with fresh air at room temperature. This approach provides an indirect measure of tidal volume, which is directly proportional to the cyclic chamber pressure signal produced during respiration in a sealed chamber. The mice were first allowed 30 min to acclimatize to the chamber, after which the recording session proceeded for 3 h. Breathing measures recorded every 2 s were time-linked to the EEG-predicted sleep state. Only data points for which the sleep/wake state was identified were included in the analysis, with no other exclusion criteria being applied post data collection. However, mice showing >3 standard deviations from the mean in EEG were excluded from analysis. One lesioned mouse with a 10 fold reduced breathing frequency during sleep (compared to all other mice) was excluded from analysis. For each mouse, the values for each breathing measure during sleep (REM=NREM) and the wake period were averaged. Data was analyzed by two way ANOVA (sex, lesion) pairing the sleep and wake state measured for each mouse. The variability of each parameter for each mouse was also calculated using Levene’s test of equality of variances in which, for each mouse, that average value for each parameter was subtracted from all values and the resulting data compared between cMPT-lesioned or control groups by one way ANOVA.

**Arterial oxygen saturation.** The arterial oxygen saturation was recorded on unrestrained awake mice either in room air or in the environmental chamber using a MouseOx Plus oximeter (Starr Life Sciences) in accordance with the manufacturer’s instructions. Data were collected for at least 30 min and only used when no error code was given. Oxygen saturation levels were then calculated as an average per mouse, and per experimental condition.

**Open field.** The open field test was performed in a square white Plexiglas box (30 cm × 30 cm) for 30 min. The chamber was divided into a central field (center, 15 cm × 15 cm) and an outer field (border). The mouse’s movement was recorded using a video camera, and analyzed using the EthoVision XT video tracking system v14/15 (Noldus Information Technology). Total track length was calculated using the center of the animal’s body as the reference point.

**Y maze.** The Y-maze was composed of three equally spaced arms (120° apart, 35 cm long, and 10 cm wide) made of Perspex. During training, the mice were placed in one of the arms (the start arm) with access to only one other arm for a period of 15 min. One day after the training, mice were allowed to explore in the Y-maze for 10 min with access to all three arms. Animals were tracked using EthoVision XT software, and the total time and the percent time spent in each arm were analyzed.

**Novel object recognition.** The task procedure consisted of three phases: habituation, familiarization, and the test phase. In the habituation phase, the mice were allowed to freely explore the open-field arena (40 cm × 40 cm) for 5 min. During the familiarization phase, they were placed in the arena containing two identical sample objects, for 5 min, where both objects were located in opposite and symmetrical corners of the arena. After a 1 h retention interval, the mice were returned to the arena with two objects, one identical to the sample and the other novel, and were allowed to explore again for 5 min. Animals were tracked using EthoVision XT software and the percent time spent exploring the objects were analyzed.

**Active place avoidance.** The apparatus (Bio-Signal Group) consisted of an elevated arena with a grid floor fenced with a transparent circular boundary, located in a room with visual cues on the walls67. The arena rotated clockwise (1 rpm) and an electric shock could be delivered through the grid floor. On the day after habituation, mice underwent daily training sessions for 4 or 5 days, lasting for 10 min per day in which the mouse was trained to avoid a 60° shock zone, entrance to which led to the delivery of a brief foot shock (500 ms, 0.5 mA). To determine their memory of the shock zone, 24 h after the last training session, the mice were allowed to explore the arena for 10 min without shocks being applied. The position of the animal in the arena was tracked using an overhead camera linked to Tracker software v2.1 (Bio-Signal Group).

**Passive place avoidance.** The passive place avoidance behavioral paradigm was used to test basal forebrain-dependent idiotiotic navigation108,109. This navigation task used the same apparatus as the active place avoidance task. However, all external cues were eliminated to minimize allocentric navigation, the circular boundary was an opaque gray, and the arena remained stationary throughout the experiment. The mice went through a 5 min habituation session and then a 10 min training phase with a 1 h interval between them. Twenty-four hours after the training session, the mice were allowed to explore the arena for 5 min without shocks being applied111.

**Morris water maze.** Mice were trained to escape the maze by finding a platform submerged 1.5 cm beneath the surface of the water and invisible to the mice while swimming. Three trials were performed per day, or 60 s each with 30 min between trials. During each trial, mice
were placed into the tank at one of three designated starting points in a pseudorandom order. If the mice failed to find the platform within 60 s, they were manually guided to it and allowed to remain there for at least 20 s. Mice were trained for 5 days as needed to reach the training criterion of 15 s (escape latency). The probe trial occurred 24 h after the last training session and consisted of a 60 s trial without the platform. Performance was measured following tracking with the EthoVision XT video tracking system.

Sleep deprivation. To induce sleep deprivation, up to 8 mice were placed in a water-filled cage (35 cm × 25 cm) that contained 9 cylinders (3 cm diameter) with 1 cm above the water surface (Supplementary Fig. 7A). The sleep deprivation cages and control cages, which also contained cylinders but no water inside, were held within a climate chamber on a 12:12 h light:dark cycle at 27 °C and 25% relative humidity. Mice were placed in the sleep deprivation cages for 20 h a day and in their home cages (4 to a cage), also within the climate cabinet, for 4 h per day during their light cycle. Mice were monitored by video and weighed daily.

2ME2 treatments

Two weeks post-surgery, the cMPT-lesioned mice were treated with either a HIF-1α inhibitor 2-methoxyestradiol (2ME2, Sigma-Aldrich, M6383), or vehicle control (saline with 0.5% DMSO). The 2ME2 was dissolved in saline at a concentration of 0.5 mg/ml with 0.5% DMSO. Mice received daily i.p. injections of either 2ME2 (15 mg/kg body weight) or vehicle for 3 or 4 weeks. Mice were weighed every third day and in their home cages (4 to a cage), also within the climate cabinet, for 4 h per day during their light cycle. Mice were monitored by video and weighed daily.

Immunohistochemistry

For immunofluorescence labeling, free-floating sections were probed using the following primary antibodies: goat anti-ChAT (1:400, AB144P, Millipore), mouse anti-parvalbumin (1:1000, MAB1572, Millipore), rabbit anti-calbindin (1:2000, CB38, Swant), mouse anti-Aβ (6E10, 1:500, Sig-39320, Convance), rabbit anti-GFAP (1:500, Z0334, Dako), rat anti-CD68 (FA-11, 1:500, MCA957, AbD Serotec), and rabbit anti-HIF-1α (1:200, NB100-479, Novus Biologicals) followed by the appropriate secondary antibody (1:1000, Life Technologies) or incubated with thiouavidin-S (0.1% in water, T1892, Sigma-Aldrich). Sections were mounted onto slides and coverslipped using fluorescent mounting medium (Dako).

For DAB (3,3′-diaminobenzidine) staining of cholinergic axons in the cortex, the biotinylated donkey secondary antibodies (1:1000, Jackson ImmunoResearch Laboratories) and ABC reagent (Vector Laboratories) were applied following the primary antibody incubation and followed by the nickel-intensified DAB reaction. Brain slices were mounted on slides and coverslipped with DPX mounting medium (Sigma-Aldrich).

ELISA methods

While mice were perfused with PBS, after which the cortex and hippocampus were dissected, weighed, and snap-frozen with liquid nitrogen. The protein was extracted by adding ice-cold 10 v/v RIPA buffer (250 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris HCl, pH 8.0, containing Roche Complete™ protease inhibitor cocktail and PhosSTOP phosphatase inhibitor cocktail and 1 mM AEBSF) to the tissue before homogenization using Bullet Blender Storm 24 (Next Advance). The level of Aβ in the tissue was assessed by ELISA as per the manufacturer's instructions (KHB3442, Invitrogen). The resulting measurements were normalized for tissue weight.

Imaging was performed using either an upright fluorescence microscope (Axio Imager, Zeiss Zen; 2012, Carl Zeiss) Slidebook v6.0 (3i Inc.), Nikon NIS, and vSlide Scanner (Metafer, Metasystems), or a Diskoveroy spinning disc confocal microscope (Andor, Oxford Instruments). All measurements and analyses were performed using Imaris 9.2.1 software (Bitplane) or Image J v1.45 (NIH). MPT and basal forebrain cell counts were obtained from every 3rd section of a 3 series of the relevant anatomical region as defined by the Mouse Brain Atlas. The total cell count per mouse was summed and graphed. Uil-SAP-injected mice not displaying a loss of cMPT neurons of >10% from the mean of controls were excluded from further analysis. Axonal density analyses of cBF neurons were undertaken using ImageJ. For each animal, 5 somatosensory cortex-containing brain slices were selected at random and the level of CHAT immunostaining was analyzed by measuring the gray value along one line per cortical layer. These values were then pooled, averaged, and inversed to obtain the average axon density for each animal (Boskovic et al.).

Statistical analysis

Statistical analysis was performed using GraphPad Prism software (versions 7–9), accounting for appropriate distribution and variance to ensure proper statistical parameters were applied. Prism files containing source data and statistical outcomes (including confidence intervals) are available in the Prism files in the Source data. Levene tests were performed using the program R. Graphed values are expressed as the mean ± s.e.m (except where stated as s.d) with significance determined at P < 0.05. Data from different cohorts of mice that had undergone the same procedures were combined for analyses.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Source data are provided with this paper as a Source Data file. This together with raw and processed data generated in this study, including statistical calculations, have been deposited at: https://doi.org/10.48610/81462a6. Any raw data files not deposited are available from the corresponding author. Source data are provided with this paper.

References

1. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
2. Karran, E. & De Strooper, B. The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics. Nat. Rev. Drug Discov. 21, 306–318 (2022).
3. Zhu, X. & Zhao, Y. Sleep-disordered breathing and the risk of cognitive decline: A meta-analysis of 19,940 participants. Sleep, Breath., Schlaf Atm. 22, 165–173 (2018).
4. Punjabi, N. M. The epidemiology of adult obstructive sleep apnoea. Proc. Am. Thorac. Soc. 5, 136–143 (2008).
5. Yaffe, K., Falvey, C. M. & Hoang, T. Connections between sleep and cognition in older adults. Lancet Neurol. 13, 1017–1028 (2014).
6. Daulatzai, M. A. Evidence of neurodegeneration in obstructive sleep apnoea: Relationship between obstructive sleep apnoea and cognitive dysfunction in the elderly. J. Neurosci. Res. 93, 1778–1794 (2015).
7. Ancoli-Israel, S. et al. Cognitive effects of treating obstructive sleep apnoea in Alzheimer’s disease: A randomized controlled study. J. Am. Geriatr. Soc. 56, 2076–2081 (2008).
8. Osorio, R. S. et al. Greater risk of Alzheimer’s disease in older adults with insomnia. J. Am. Geriatr. Soc. 59, 559–562 (2011).
9. Yun, C. H. et al. Amyloid burden in obstructive sleep apnoea. J. Alzheimers Dis. 59, 21–29 (2017).
10. Sharma, R. A. et al. Obstructive sleep apnea severity affects amyloid burden in cognitively normal elderly. A longitudinal study. Am. J. Respir. Crit. Care Med. 197, 933–943 (2018).

11. André, C. et al. Association of sleep-disordered breathing with Alzheimer disease biomarkers in community-dwelling older adults: A secondary analysis of a randomized clinical trial. JAMA Neurol. 77, 716–724 (2020).

12. Livingston, G. et al. Dementia prevention, intervention, and care. Lancet 390, 2673–2734 (2017).

13. Yaffe, K. et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 306, 613–619 (2011).

14. Shiota, S. et al. Chronic intermittent hypoxia/reoxygenation facilitate amyloid-beta generation in mice. J. Alzheimers Dis. 37, 325–333 (2013).

15. Row, B. W., Kheirandish, L., Cheng, Y., Rowell, P. P. & Gozal, D. Impaired spatial working memory and altered choline acetyltransferase (CHAT) immunoreactivity and nicotinic receptor binding in rats exposed to intermittent hypoxia during sleep. Behav. Brain Res. 177, 308–314 (2007).

16. Mander, B. A., Winer, J. R., Jagust, W. J. & Walker, M. P. Sleep: A novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer’s disease? Trends Neurosci. 39, 552–566 (2016).

17. Wang, G., Grone, B., Colas, D., Appelbaum, L. & Mourrain, P. Synaptic plasticity in sleep. Learning, homeostasis and disease. Trends Neurosci. 34, 452–463 (2011).

18. Woolf, N. J. & Butcher, L. L. Cholinergic systems in the rat brain: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain. Brain Res. Bull. 16, 603–637 (1986).

19. Zhang, B. et al. Impaired rapid eye movement sleep in the Tg2576 APP murine model of Alzheimer’s disease with injury to pedunculopontine cholinergic neurons. Am. J. Pathol. 167, 1361–1369 (2005).

20. Van Dort, C. J. et al. Optogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep. Proc. Natl Acad. Sci. USA 112, 584–589 (2015).

21. Lu, J., Sherman, D., Devor, M. & Saper, C. B. A putative flip-flop switch for control of REM sleep. Nature 441, 589–594 (2006).

22. Bellingham, M. C. & Berger, A. J. Prenatal depression of excitatory synaptic inputs to rat hypoglossal motoneurons by muscarinic M2 receptors. J. Neurophysiol. 76, 3758–3770 (1996).

23. Mizuno, S., Kameda, A., Inagaki, T. & Horiguchi, J. Effects of donepezil on Alzheimer’s disease: The relationship between cognitive function and rapid eye movement sleep. Psychiatry Clin. Neurosci. 58, 660–665 (2004).

24. Irnak, S. O. & de Lecea, L. Basal forebrain cholinergic modulation of sleep transitions. Sleep 37, 1941–1951 (2014).

25. Clark, S. D. et al. Urotensin II acts as a modulator of mesopontine cholinergic neurons. Brain Res. 19, 139–148 (2005). 1059.

26. Clark, S. D. et al. The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. Brain Res. 923, 120–127 (2001).

27. Jegou, S. et al. Localization of the urotensin II receptor in the rat central nervous system. J. Comp. Neurol. 495, 21–36 (2006).

28. Xiao, C. et al. Cholinergic mesopontine signals govern locomotion and reward through dissociable midbrain pathways. Neuron 90, 333–347 (2016).

29. Sunshine, M. D. & Fuller, D. D. Automated classification of whole body plethysmography waveforms to quantify breathing patterns. Front. Physiol. 12, 680265 (2021).

30. Ramirez, J. M. et al. Central and peripheral factors contributing to obstructive sleep apneas. Respir. Physiol. Neurobiol. 189, 344–353 (2013).

31. Palmer, L. A. et al. Hypoxia-induced ventilatory responses in conscious mice: Gender differences in ventilatory roll-off and facilitation. Respir. Physiol. Neurobiol. 185, 497–505 (2013).

32. Zhao, Z., Zhao, X. & Veasey, S. C. Neural consequences of chronic short sleep: Reversible or lasting? Front. Neurol. 8, 235 (2017).

33. Hampel, H. et al. Revisiting the cholinergic hypothesis in Alzheimer’s disease. Emerging evidence from translational and clinical research. J. Prev. Alz Dis. 6, 2–15 (2019).

34. Baxter, M. G. & Chiba, A. A. Cognitive functions of the basal forebrain. Curr. Opin. Neurobiol. 9, 178–183 (1999).

35. Grothe, M. J., Ewers, M., Krause, B., Heinsen, H. & Teipel, S. J. & Alzheimer’s Disease Neuroimaging I. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement. 10, S344–S353 (2014).

36. Kerbler, G. M. et al. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer’s disease. NeuroImage Clin. 7, 105–113 (2015).

37. Chiesa, P. A. et al. Relationship between basal forebrain resting-state functional connectivity and brain amyloid-β deposition in cognitively intact older adults with subjective memory complaints. Radiology 290, 167–176 (2018).

38. Sotthibundhu, A. et al. Aβ-amyloid1-42 induces neuronal death through the p75 neurotrophin receptor. J. Neurosci. 28, 3941–3948 (2008).

39. Knowles, J. K. et al. The p75 neurotrophin receptor promotes amyloid-β1-42-induced neuritic dystrophy in vitro and in vivo. J. Neurosci. 29, 10627–10637 (2009).

40. Gil-Bea, F. J. et al. Cholinergic denervation exacerbates amyloid pathology and induces hippocampal atrophy in Tg2576 mice. Neurobiol. Dis. 48, 439–446 (2012).

41. Laursen, B., Mork, A., Plath, N., Kristiansen, U. & Bastlund, J. F. Impaired hippocampal acetylcholine release parallels spatial memory deficits in Tg2576 mice subjected to basal forebrain cholinergic degeneration. Brain Res. 1543, 253–262 (2014).

42. Turnbull, M. T., Boskovic, Z. & Coulson, E. J. Acute down-regulation of BDNF signaling does not replicate exacerbated amyloid-β levels and cognitive impairment induced by cholinergic basal forebrain lesion. Front. Mol. Neurosci. 11, 51 (2018).

43. Hamlin, A. S., Windels, F., Boskovic, Z., Sah, P. & Coulson, E. J. Lesions of the basal forebrain cholinergic system in mice disrupt idiotic navigation. PLoS One 8, e53472 (2013).

44. Machado, R. B., Hipólido, D. C., Benedito-Silva, A. A. & Tufik, S. Sleep deprivation induced by the modified multiple platform technique: Quantification of sleep loss and recovery. Brain Res. 1004, 45–51 (2004).

45. Dayan, F., Roux, D., Brahimi-Horn, M. C., Pouyssegur, J. & Mazure, N. M. The oxygen sensor factor- inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1α. Cancer Res. 66, 3688–3698 (2006).

46. Arias-Cavieiras A, et al. A HIF1a-dependent pro-oxidant state disrupts synaptic plasticity and impairs spatial memory in response to intermittent hypoxia. eNeuro 7, ENEURO.0024-20.2020 (2020).

47. Iyalomhe, O. et al. The role of hypoxia-inducible factor 1 in mild cognitive impairment. Cell Mol. Neurobiol. 37, 969–977 (2017).

48. Ward, N. R. et al. The effect of respiratory scoring on the diagnosis and classification of sleep disordered breathing in chronic heart failure. Sleep 36, 1341–1348 (2013).

49. Burgess, K. R. New insights from the measurement of loop gain in obstructive sleep apnoea. J. Physiol. 590, 1781–1782 (2012).

50. McKenna, J. T. et al. Basal forebrain parvalbumin neurons mediate arousals from sleep induced by hypercarbia or auditory stimuli. Curr. Biol. 30, 2379–2385.e4 (2020).
63. Adams, N., Eckert, D. J. & Jordan, A. S. Obstructive sleep apnoea pathogenesis from mild to severe: Is it all the same? Respir. Sleep. Dis. 22, 33–42 (2017).
64. Bosi, M. et al. Qualitative phenotyping of obstructive sleep apnoea and its clinical usefulness for the sleep specialist. Int. J. Environ. Res. Public Health 17, 2058 (2020).
65. Groeneveld, M., Heinsen, H. & Teipel, S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer’s disease. Neurobiol. Aging 34, 1210–1220 (2013).
66. Hoft, J. et al. Effect of Donepezil in Alzheimer disease can be measured by a computerized human analog of the Morris water maze. Neurodegen. Dis. 13, 192–196 (2014).
67. Kerbler, G. M. et al. Basal forebrain atrophy contributes to allocentric navigation impairment in Alzheimer’s disease patients. Front. Aging Neurosci. 7, 105–113 (2015).
68. Canessa, N. et al. Obstructive sleep apnea: Brain structural changes and neurocognitive function before and after treatment. Am. J. Respir. Crit. Care Med. 183, 1419–1426 (2011).
69. Itif, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 4, 147ra111 (2012).
70. Ju, Y. E. et al. Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid. Ann. Neurol. 80, 154–159 (2016).
71. Greferath, U., Bennie, A., Kourakis, A. & Barrett, G. L. Impaired spatial learning in aged rats is associated with loss of p75-positive neurons in the basal forebrain. Neuroscience 100, 363–373 (2000).
72. Cavadas, M. A. S., Cheong, A. & Taylor, C. T. The regulation of transcriptional repression in hypoxia. Exp. Cell Res. 356, 173–181 (2017).
73. Martinez, C. A., Kerr, B., Jin, C., Cistulli, P. A. & Cook, K. M. Obstructive sleep apnoea activates HIF-1 in a hypoxia dose-dependent manner in HCT116 colorectal carcinoma cells. Int. J. Mol. Sci. 20, 445 (2019).
74. Navarrete-Opazo, A. & Mitchell, G. S. Therapeutic potential of intermittent hypoxia: A matter of dose. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307, R181–R197 (2014).
75. Adams, N., Strauss, M., Schluchter, M. & Redline, S. Relation of measures of sleep-disordered breathing to neuropsychological function. Am. J. Respir. Crit. Care Med 163, 1626–1631 (2001).
76. Findlay, L. J. et al. Cognitive impairment in patients with obstructive sleep apnoea and associated hypoxemia. Chest 90, 686–690 (1986).
77. Incalzi, R. A. et al. Does cognitive dysfunction conform to a distinctive pattern in obstructive sleep apnoea syndrome? J. Sleep. Res. 13, 79–86 (2004).
78. Spira, A. P. et al. Objectively measured sleep and β-amyloid burden in older adults: A pilot study. SAGE Open Med. 2, 2050312114546520 (2014).
79. Osorio, R. S. et al. Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms. Neurodegener. Dis. 13, 163–165 (2014).
80. Osorio, R. S. et al. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer’s disease in cognitively normal elderly individuals. Neurobiol. Aging 35, 1318–1324 (2014b).
81. Zhang, X. et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and β-amyloid generation. J. Biol. Chem. 282, 10873–10880 (2007).
82. Villa, J. C. et al. Nontranscriptional role of Hif-1α in activation of γ-secretase and Notch signaling in breast cancer. Cell Rep. 8, 1077–1092 (2014).
83. Hartig, W. et al. Immunolesion-induced loss of cholinergic projection neurons promotes β-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice. Neuropathol. Appl. Neurobiol. 40, 106–120 (2014).
84. Ramos-Rodriguez, J. J. et al. Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. J. Neuropathol. Exp. Neurol. 72, 272–285 (2013).
85. Boskovic, Z. et al. The role of p75NTR in cholinergic basal forebrain morphology and function. J. Neurosci. 34, 13033–13038 (2014).
86. Qian, L. et al. removal of p75 neurotrophin receptor expression from cholinergic basal forebrain neurons reduces amyloid-β plaque deposition and cognitive impairment in aged APP/PS1 mice. Mol. Neurobiol. 56, 4639–4652 (2018).
87. Fisher, A. et al. AF710B, a novel M1/sigma1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease. Neurodegener. Dis. 16, 95–110 (2016).
88. Rossner, S., Ueberham, U., Schliebs, R., Perez-Polo, J. R. & Bigl, V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56, 541–569 (1998).
89. Welt, T. et al. Acute effects of muscarinic M1 receptor modulation on AβPP metabolism and amyloid-β levels in vivo: A microdialysis study. J. Alzheimers Dis. 46, 971–982 (2015).
90. Teipel, S. et al. Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer’s disease. Neurobiol. Aging 35, 482–491 (2014).
91. Schmitz, T. W., Nathan Spreng, R. & Alzheimer’s Disease Neuroimaging I. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology. Nat. Commun. 7, 13249 (2016).
92. Owen, J. E., Benedikts, D., Ottir, B., Gislaason, T. & Robinson, S. R. Neuropathological investigation of cell layer thickness and myelination in the hippocampus of people with obstructive sleep apnoea. Sleep 42, 1–13 (2019).
93. Richards, K. C. et al. CPAP adherence may slow 1-year cognitive decline in older adults with mild cognitive impairment and apnoea. J. Am. Geriatr. Soc. 67, 558–564 (2019).
94. Spira, A. P. & Gottesman, R. F. Sleep disturbance: An emerging opportunity for Alzheimer’s disease prevention? Int. Psychogeriatr. 29, 529–531 (2017).
95. Longo, F. M. & Massa, S. M. Small-molecule modulation of neurotrophin receptors: A strategy for the treatment of neurodegenerative disease. Nat. Rev. Drug Discov. 12, 507–525 (2013).
96. Tang, X. & Sanford, L. D. Telemetric recording of sleep and home cage activity in mice. Sleep 25, 691–699 (2002).
97. Papazoglou, A. et al. Non-restraining EEG radiotomometry: Epidural and deep intracerebral stereotaxic EEG electrode lacement. J. Vis. Exp. 112, 54216 (2016).
98. Hernandez, A. B. et al. Novel whole body plethysmography system for the continuous characterization of sleep and breathing in a mouse. J. Appl. Physiol. 112, 671–680 (2012).
99. Cimadevilla, J. M., Kaminsky, Y., Fenton, A. & Bures, J. Passive and active place avoidance as a tool of spatial memory research in rats. J. Neurosci. Methods 102, 155–164 (2000).

Acknowledgements
This work was supported by the National Health and Medical Research Council of Australia (GNT1049236 to E.J.C. and M.C.B.; GNT 1162505 to E.J.C.; GNT1186943 to O.R.), Dementia Australia Research Foundation, the Brain Foundation, the Mason Foundation and the Clem Jones Center for Ageing Dementia Research. We thank Advance Targeting Systems for their generous supply of UII-SAP and Blank-SAP. Work was performed in the School of Biomedical Sciences’ and Queensland Brain Institute’s Advanced Microscopy Facilities with support from Shaun Walters and Luke Hammond respectively, and the Queensland Brain Institute’s Animal Behavioral Facility with support from Daniel Blackmore, and the School of Biomedical Sciences Integrated Physiology Facility with support from Stuart Mazzone and Melanie Flint. We thank Queensland Brain Institute’s Nature Communications | (2022)13:6543 17

https://doi.org/10.1038/s41467-022-33624-y

Nature Communications | (2022)13:6543
Animal Facility staff, particularly Liesel MacDonald, as well as Michael Lardelli (The University of Adelaide, Australia) for helpful suggestions regarding hypoxia, Bree Rumballe for excellent laboratory management and discussion, and Rowan Tweedale for manuscript editing.

Author contributions
L.Q., O.R., M.C.B., and E.J.C. designed the experiments, L.Q., O.R., L.K., M.R.M., N.G., K.S., N.M., P.R.K., and A.S. performed experiments, L.Q., L.Q., O.R., L.K., M.R.M., N.G., K.S., N.M., M.W.D., M.C.B., and E.J.C. analyzed data, all authors discussed the work, and wrote or commented on the manuscript.

Competing interests
The authors report no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-33624-y.

Correspondence and requests for materials should be addressed to Elizabeth J. Coulson.

Peer review information Nature Communications thanks Ricardo Osorio, Hermona Soreq and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© Crown 2022